ReviewACS medicinal chemistry letters2023
Beyond 20 in the 21st Century: Prospects and Challenges of Non-canonical Amino Acids in Peptide Drug Discovery.
Review in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- Interpretable machine learning framework for peptide lead optimization in ultralarge design spaces.npj drug discovery · 2026Article
- Asymmetric synthesis and antifungal evaluation of arylalkylamine-functionalized β-substituted (s)-α-alanine analogues.Amino acids · 2026Article
- Peptide Thioester and Triazole Derivatives Through On-Resin Dual-Modification of Peptide Thiosulfonates.Angewandte Chemie (International ed. in English) · 2026Article
- Applications and limitations of AI tools in enzyme design.Protein science : a publication of the Protein Society · 2026Review
- Late-Stage Functionalization of Peptides on the Solid Phase.Angewandte Chemie (International ed. in English) · 2026Review
- Direct Stereospecific Deoxyamination of Alcohols Enabled by Li-Mediated SuFEx.Organic letters · 2026Article
- Photoredox-Catalyzed Lysine C(spJournal of the American Chemical Society · 2026Article
- Bridging Algorithms and Biocatalysis: Perspectives on AI-Supported Enzyme Engineering.Molecules (Basel, Switzerland) · 2026Review
- Functional Engineering of Bioactive Peptides: Chemical Modifications and Synthetic Biology Approaches.International journal of molecular sciences · 2026Review
- Engineering Protease-Resistant Peptides via Non-Canonical Amino Acids: Design Strategies and Biosynthetic Advances.Bioengineering (Basel, Switzerland) · 2026Review
- Scaling SMILES-based chemical language models for therapeutic peptide engineering.bioRxiv : the preprint server for biology · 2026Article
- Continuous-Flow Asymmetric Photocatalysis for the Synthesis of Natural and Unnatural α‑Amino Acid Derivatives.ACS organic & inorganic Au · 2026Article
- Directed Evolution of Threonine Aldolases for the Photobiocatalytic Synthesis of β-Branched-α-Tetrasubstituted and Other Noncanonical Amino Acids.Journal of the American Chemical Society · 2026Article
- Engineering Enantiocomplementary Protoglobins for Stereoconvergent Construction ofJournal of the American Chemical Society · 2026Article
- Nickel-Photocatalytic Deoxygenative Arylation toward β-Methyl-Branched α-Amino Acids.Organic letters · 2026Article
- Article
- A general route to β,β-carbocyclic sidechains in peptides: an aqueous metallaphotoredox approach driven by green light.Chemical science · 2026Article
- Kinetic resolution of amino acids by phosphine oxide catalyzed enantioselective esterification.Nature communications · 2026Article
- Peptides and Amino Acids in Drug Development: Where We Stand and Where We Must Go.Biomedicines · 2026Article
- EDA Complex-Mediated C(spEuropean journal of organic chemistry · 2026Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Life is constructed primarily using a toolbox of 20 canonical amino acids-relying upon these building blocks for the assembly of proteins and peptides that regulate nearly every cellular task, including cell structure, function, and maintenance. While Nature continues to be a source of inspiration for drug discovery, medicinal chemists are not beholden to only 20 canonical amino acids and have begun to explore non-canonical amino acids (ncAAs) for the construction of designer peptides with improved drug-like properties. However, as our toolbox of ncAAs expands, drug hunters are encountering new challenges in approaching the iterative peptide design-make-test-analyze cycle with a seemingly boundless set of building blocks. This Microperspective focuses on new technologies that are accelerating ncAA interrogation in peptide drug discovery (including HELM notation, late-stage functionalization, and biocatalysis) while shedding light on areas where further investment could not only accelerate the discovery of new medicines but also improve downstream development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.